TII
10.11.2020 13:09:04 CET | Business Wire | Press release
Abu Dhabi has unveiled the Technology Innovation Institute (TII), a pioneering global centre for advanced technology research committed to reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation and advanced technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005653/en/
The institute is the dedicated applied research pillar of the Advanced Technology Research Council (ATRC), which was recently established to set the research and development (R&D) priorities for Abu Dhabi.
It aims to deliver discovery science and breakthrough technologies that have a global impact. It is rapidly breaking new ground at its seven initial dedicated research centres, which each have world-class research facilities.
The initial seven areas of focus are: quantum research; autonomous robotics; cryptography; advanced materials; digital security; directed energy; and secure systems.
His Excellency Faisal Al Bannai, Secretary-General of Advanced Technology Research Council, said the institute would help position Abu Dhabi and the UAE as a global hub for advanced technology research.
HE Faisal said: “The Technology Innovation Institute is a pioneering research centre that develops disruptive and transformative technologies that have practical use-cases and global impact. The institute allows us to push the frontiers of knowledge further than ever before for the benefit of science, society, the economy and the environment.”
Teams of international scientists and researchers joined the institute from around the world within two months of the first board meeting in August 2020. This intellectual community will contribute to building a research and development (R&D) ecosystem in Abu Dhabi and the UAE.
TII will also drive applied research, intellectual property development, and academic and industry partnerships. It has already begun working on more than 25 long-term collaborative projects through partnerships with more than 20 world-leading universities.
Importantly, the institute will have the flexibility to rapidly progress research, with a defined research roadmap, committed long-term funding and the ability to make effective decisions in a fast-paced environment.
TII is one of two pillars under ATRC, which was established in May 2020 to expand the breadth and depth of an already thriving R&D ecosystem in Abu Dhabi. Bringing together cross-disciplinary leaders in research and technology, ATRC is cultivating a collaborative research community, accelerating innovation and discovery and fostering a culture of inquiry.
About Technology Innovation Institute (TII):
Technology Innovation Institute, the dedicated applied research pillar of the Advanced Technology Research Council (ATRC), is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The institute has seven initial dedicated research centres, in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the institute connects an intellectual community and contributes to expanding the R&D ecosystem in Abu Dhabi and the UAE. The institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of a knowledge-based economy.
For more information, visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005653/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom